Key Capital Seeks Partners for Development of KV-C19 Coronavirus Therapeutic Vaccine Using Proven Immunotherapy Platform - Seite 2

Of specific significance in the case of COVID-19 is that almost all infectious viruses enter the host through mucous membranes. Therefore, mucosal immunity, rather than systemic, is essential to maximally protect against any such transmitted pathogens. The promise for KV-C19 is that the oral therapeutic vaccine could confer treatment and local immunity, not only at the site of delivery, but also on the surface of other mucosal membranes. This could eventually also induce systemic immunity and see the body’s own immune system kill the virus and enable the patient to achieve full recovery. 

“In the current situation, urgent treatment intervention as soon as practically possible will not only save lives, but significantly mitigate the risks of financial damage for many people individually and for businesses and global economies,” said Key Capital Corporation Chairman Mr. Peter Boonen. “We believe that we have a viable and low-cost therapeutic solution that could potentially be available to a mass global market in as little as six months. In the current situation, where the Coronavirus threatens to become pandemic; where there is increasing global fear and panic; where resources are being stretched to their limits; where the economic cost is already in trillions of dollars; we believe we have something to offer and that prospective partners will recognize we may well represent an immediate potential solution.”  

Mr. Boonen further advised; “To proceed in this imperative initiative Key Capital will require partnered investment and, therefore, welcomes inquiry and interest as through partnering with stakeholders we can be production ready within months with possibly a most viable and economically sensible solution.”

About Key Capital Corporation

Key Capital is focused on the development of social media and fintech interests. Key Capital is also working with GoldVault, in which it has a 30% interest, to prepare for a global launch of gold savings accounts in early 2020. The GoldVault accounts will offer gold savings incentives through discounts and rewards that provide the equivalent of 4.5% APY return in gold, which is up to 50 times the average savings account interest rate paid by most banks. See: www.goldvaultsaver.com